[{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/ideas.ts","type":"changed","fields":[{"field":"test","before":"\"Phase 1 of a HER2 or TROP2 radioimmunoconjugate in ADC-refractory breast cancer with antigen PET selection and dosimetry.\"","after":"\"Run a phase 1 of a HER2 or TROP2 radioimmunoconjugate in ADC-refractory breast cancer with antigen PET selection and dosimetry.\""}]},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/ideas.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"maturity"},{"field":"tldr"},{"field":"summary"},{"field":"hypothesis"},{"field":"rationale"},{"field":"test"},{"field":"technologies"},{"field":"targets"},{"field":"cancers"},{"field":"related"}]}]